H.C. Wainwright Initiates Coverage On CytomX Therapeutics Inc(CTMX). In a research note issued to the investors, the brokerage major Announces the price-target to $24 per share. The shares have been rated Buy. The rating by the stock financial advisor at H.C. Wainwright was issued on Mar 27, 2017 in a research report to their Investors and Clients.
In a different note, Nomura said it Initiates Coverage On CytomX Therapeutics Inc, according to a research note issued on Mar 2, 2017. The shares have been rated ‘Buy’ by the firm. On Jan 3, 2017, Oppenheimer said it Downgrades its rating on CytomX Therapeutics Inc. The shares have been rated ‘Perform’ by the firm.
CytomX Therapeutics Inc (CTMX) made into the market gainers list on Fridays trading session with the shares advancing 2.12% or 0.37 points. Due to strong positive momentum, the stock ended at $17.79, which is also near the day’s high of $18.48. The stock began the session at $17.5 and the volume stood at 3,03,598 shares. The 52-week high of the shares is $20.02 and the 52 week low is $9.1. The company has a current market capitalization of $651 M and it has 3,65,68,327 shares in outstanding.
CytomX Therapeutics Inc(CTMX) last announced its earnings results on Mar 2, 2017 for Fiscal Year 2016 and Q4.Company reported revenue of $6.272M. Analysts had an estimated revenue of $6.190M. Earnings per share were $-0.39. Analysts had estimated an EPS of $-0.36.
Several Insider Transactions has been reported to the SEC. On Mar 21, 2017, Ii Robert C. Goeltz (Chief Financial Officer) sold 21,517 shares at $19.80 per share price.Also, On Mar 21, 2017, Sean A. Mccarthy (President and CEO) sold 14,343 shares at $19.60 per share price.On Dec 1, 2016, Timothy M Shannon (director) sold 22,086 shares at $11.18 per share price, according to the Form-4 filing with the securities and exchange commission.
CytomX Therapeutics Inc. is a United States-based biotechnology company. The Company is engaged in developing Probody therapeutics for the treatment of cancer. Its Probody Platform designs drugs which activate in the tumor microenvironment while remaining inert in tissue and in circulation. It is also engaged in discovering and developing immunotherapy and antibody drug conjugate therapies to treat areas of medical need in oncology. The Company also focuses on applying its technology to bispecific T-cell engaging antibodies and engineered cell therapies. The Company’s pipeline focuses in two areas in research and development: Precision cancer immunotherapy and Probody drug conjugates (PDCs). The Company’s additional pipeline programs include Probody applications in the field of bispecific antibodies and engineered cell therapies.